The widespread use of serum PSA in detecting prostate cancer, beginning in the 1990s, contributed to a substantial shift in the distribution of clinical stages at the diagnosis, with ca. 95% of the malignancies diagnosed at local stages [15]. Here, KLK3 is linked to prostate cancer.